Full Text View
Tabular View
No Study Results Posted
Related Studies
D-Cycloserine Facilitation of Cocaine - Cue Extinction
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), April 2009
First Received: September 24, 2008   Last Updated: April 22, 2009   History of Changes
Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00759473
  Purpose

The purpose of this study is to explore the use of d-cycloserine to facilitate extinction of response to cocaine cues in cocaine-dependent individuals, in hopes that it may lead to the development of new treatment options for cocaine dependence.


Condition Intervention Phase
Cocaine Use Disorders
Drug: cycloserine
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: D-Cycloserine Facilitation of Cocaine - Cue Extinction

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Subjective craving of cocaine [ Time Frame: two weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • physiological responses (heart rate, skin conductance) to cocaine cues [ Time Frame: two weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 72
Study Start Date: September 2008
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
2: Experimental
DCS on days 1 and 5, placebo on days 3 and 12
Drug: cycloserine
50 mg d-cycloserine or placebo taken orally on days 1, 3, 5, and 12 of study
3: Placebo Comparator
placebo on days 1, 3, 5 and 12
Drug: cycloserine
50 mg d-cycloserine or placebo taken orally on days 1, 3, 5, and 12 of study
1: Experimental
DCS on days 1, 3, and 5; placebo on day 12
Drug: cycloserine
50 mg d-cycloserine or placebo taken orally on days 1, 3, 5, and 12 of study

Detailed Description:

Cocaine dependence remains a serious problem in the United States today and in spite of two decades of intense research, efficacious pharmacotherapeutic treatments have not been identified. Cocaine-associated environmental cues can elicit drug craving and exposure to cocaine-related cues is likely to be involved in relapse. Emerging data supports the role of glutamate in extinction learning. D-cycloserine (DCS), a partial glutamate agonist, facilitates extinction of associative learning in animal models of fear-conditioning and clinical studies of exposure treatment for anxiety disorders. A recent study demonstrated DCS acceleration of extinction of cocaine-induced conditioned place preference in rats (Botreau et al., 2006). Exploration of DCS in facilitating extinction of response to drug-related cues in humans is needed. The proposed study will extend these innovative and promising findings from the basic science arena and anxiety disorders field in a proof of concept investigation of DCS facilitation of extinction of response to cocaine-related cues in a human laboratory paradigm.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
  2. Subjects must meet DSM-IV criteria for current cocaine dependence. Subjects may meet criteria for abuse, but not dependence on any other substance with the exceptions of nicotine and alcohol. Because of the high comorbidity of cocaine and nicotine and alcohol dependence, excluding nicotine and alcohol dependence would seriously compromise the feasibility of recruitment. Nicotine use immediately prior to the cue exposure/extinction session will be controlled. Although individuals who meet criteria for alcohol abuse or dependence will be accepted for study participation, anyone who has a measurable blood alcohol level on the day of the sessions will be excluded as acute alcohol intake can increase serum levels of DCS and lower the seizure threshold.
  3. Use of one of the following methods of birth control by female subjects: barrier methods (diaphragm or condoms with spermicide or both), surgical sterilization, use of an intra-uterine contraceptive device, or complete abstinence from sexual intercourse.
  4. Subjects must live within a 50-mile radius of our research program and have reliable transportation.
  5. Subjects must consent to remain abstinent from all drugs of abuse (except nicotine) prior to the first session and through the session on day 5.
  6. Subjects must consent to random assignment to the DCS vs. placebo conditions.

Exclusion Criteria:

  1. Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.
  2. Subjects with evidence of or a history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including diabetes, as these conditions may affect heart rate or skin conductance measurement.
  3. Subjects with a history of or current psychotic disorder, current major depressive disorder, bipolar affective disorder or a severe anxiety disorder as these may impact cue reactivity.
  4. Subjects who are unwilling or unable to maintain abstinence from alcohol and other drugs of abuse (except nicotine) prior to and between the initial three cue procedures.
  5. Subjects meeting DSM-IV criteria for substance dependence (other than nicotine, cocaine, or alcohol as appropriate) within the past 60 days.
  6. Subjects currently taking B-blockers, anti-arrhythmic agents, psychostimulants or any other agents known to interfere with heart rate and skin conductance monitoring.
  7. Known or suspected hypersensitivity to DCS.
  8. Individuals taking medications that could adversely interact with study medications, including, but not limited to ethionamide, isoniazid, or amino acid supplements.
  9. Subjects with a history of epilepsy or seizure disorder.
  10. Subjects with significant liver impairment, as DCS may increase serum transaminases.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00759473

Contacts
Contact: Kimber L Price, MSCR, PhD 843-792-4847 pricekl@musc.edu

Locations
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Kimber L Price, MSCR, Ph.D.     843-792-4325     pricekl@musc.edu    
Principal Investigator: Kathleen T Brady, MD, PhD            
Sub-Investigator: Kimber L Price, PhD            
Sub-Investigator: Therese Killeen, PhD            
Sub-Investigator: Megan M Moran-Santa Maria, PhD            
Sub-Investigator: Michael E Saladin, PhD            
Sub-Investigator: Rickey E Carter, PhD            
Sub-Investigator: Karen Hartwell, MD            
Sub-Investigator: Bryan K Tolliver, MD, PhD            
Sub-Investigator: Peter Kalivas, PhE            
Sub-Investigator: Robert Malcolm, MD            
Sub-Investigator: Aimee L McRae-Clark, Pharm D            
Sponsors and Collaborators
Investigators
Principal Investigator: Kathleen T Brady, M.D., Ph.D. Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Medical University of South Carolina ( Kathleen T. Brady, M.D., Ph. D. )
Study ID Numbers: HR#17972, R01-DA-023188, DPMCDA
Study First Received: September 24, 2008
Last Updated: April 22, 2009
ClinicalTrials.gov Identifier: NCT00759473     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute on Drug Abuse (NIDA):
substance-related disorders

Study placed in the following topic categories:
Antimetabolites
Cycloserine
Anti-Bacterial Agents
Anti-Infective Agents
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Anti-Infective Agents, Urinary
Antitubercular Agents
Cocaine

Additional relevant MeSH terms:
Cycloserine
Antimetabolites
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Disorders of Environmental Origin
Anti-Infective Agents, Urinary
Renal Agents
Pharmacologic Actions
Antibiotics, Antitubercular
Anti-Bacterial Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Antitubercular Agents

ClinicalTrials.gov processed this record on September 11, 2009